Agenus reports $4.2M initial BOT+BAL revenue; net loss narrows to $3.1M in FY2025

AGENUS INC

Pre-commercial product revenue of $4.2M from early access programs in France and paid NPP across 30+ countries.
BOT+BAL shows 42% two-year OS and ~21-month median OS in heavily pretreated MSS mCRC; Phase 3 BATTMAN trial initiated.
France AAC expanded to ovarian cancer and sarcoma in January 2026; 200+ physician inquiries received globally.
Zydus collaboration provided $91M upfront capital; $20M contingent payment triggered in March 2026 for manufacturing.
Q4 2025 operating income $14.4M; full year net loss $3.1M vs prior year; other revenue $110M (non-cash royalty).

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

AGENUS INC reported financial results for the fourth quarter ended December 31, 2025.

Period: the fourth quarter ended December 31, 2025
Result: reported results

Exact text from the filing

On March 16, 2026, Agenus Inc. announced its financial results for the quarter and year ended December 31, 2025.

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

AGENUS INC reported financial results for the full year ended December 31, 2025.

Period: the full year ended December 31, 2025
Result: reported results

Exact text from the filing

On March 16, 2026, Agenus Inc. announced its financial results for the quarter and year ended December 31, 2025.

View on SEC.gov

168 earnings releases filed in the last 30 days. Browse all earnings releases →

AGENUS INC filing history →

Source: SEC EDGAR

accession 0001193125-26-107288

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.